In recent months, CMI began redirecting many of its efforts to better understand how the human microbiome is involved in the development and severity of COVID-19.
Researchers have since been evaluating samples from patients worldwide to find biological and epidemiological discoveries about the SARS-CoV-2 virus.
CMI director Rob Knight also noted the importance of a reliable HPC technology solution as the Center steps up its groundbreaking efforts to study the RNA microbiome, which is especially relevant because COVID-19 is an RNA virus.
CMI has been working with Panasas since 2015, when they were looking to create an HPC storage infrastructure that could deliver consistently high performance, speed data exploration and discovery, and simplify storage management for administrators.
The CMI team appreciates technology solutions that don't distract researchers from the scientific problems they aspire to solve. By freeing researchers from worries about storage, CMI can accelerate the adoption of advanced scientific technologies.
ActiveStor is a turnkey HPC storage appliance that runs the PanFS parallel file system to accelerate performance at every stage of the computational research process.
It delivers unlimited performance scaling and features a balanced node architecture that prevents hot spots and bottlenecks by automatically adapting to dynamically changing workloads and increasing demands - all at the industry's lowest total cost of ownership.
Panasas delivers high-performance computing data storage solutions that support industry and research innovation around the world.
Affimed N.V. announces launch of AFM28 blood cancer trial
Cardiff Oncology doses first subject with onvansertib in Phase two ONSEMBLE trial
Kintor Pharmaceutical completes subject enrolment in phase three KX-826 clinical trial in China
FDA removes partial clinical hold on Blueprint Medicines' Phase 1/2 BLU-222 trial
CSL opens Massachusetts research and development centre
BJ Bioscience signs clinical trial collaboration and supply agreement with Merck
DermBiont Touts Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel